Group 1 - The company holds an 11.1111% stake in New Anjin [2] - New Anjin's individualized drug injection P01 is currently advancing clinical trials as planned [2]

Group 1 - The core point of the article is the progress of clinical trials for Nuanzin's personalized drug injection P01, which is the world's first personalized tumor neoantigen peptide vaccine approved by both Chinese and American drug regulatory authorities [2][3] - New Source (300109.SZ) holds an 11.1111% stake in Nuanzin and has confirmed that the clinical trials for P01 are progressing as planned [2] - The company emphasizes its commitment to timely, fair, and significant information disclosure in compliance with legal obligations [2]